The topographic distributions of amyloid plaque deposition and NFT accumulation are used to assess the level of AD neuropathological change (ADNC), as reflected by the “ABC” score in the NIA-AA neuropathological guidelines (1,2): The Amyloid component is derived from the topographic distribution of any plaque type using the Thal amyloid phase (48); the tau component relies on the Braak tangle stage (49,50); and, given the significance of neuritic plaques, an additional amyloid component is accounted for by the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) score (51). The gene discussed is MAPT; the disease is Alzheimer disease.